CAGNETTA, ANTONIA
 Distribuzione geografica
Continente #
EU - Europa 4.547
Totale 4.547
Nazione #
IT - Italia 4.547
Totale 4.547
Città #
Genova 3.199
Genoa 570
Rapallo 522
Vado Ligure 248
Bordighera 8
Totale 4.547
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 173
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 170
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 167
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment 165
APO866 activity in hematologic malignancies: a preclinical in vitro study. 157
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 144
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 133
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 133
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 132
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 124
New insights into biology of chronic myeloid leukemia: implications in therapy. 123
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 122
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 121
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 121
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 119
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 118
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 116
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 116
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 113
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 112
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 109
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications 106
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 106
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 106
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 105
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 104
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 104
Intracellular NAD+ depletion induces autophagic-death in Multiple Myeloma cells 104
MiR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth 100
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 94
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma 94
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma 91
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 91
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 86
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 85
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 78
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells 69
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 64
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 56
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 52
The non-coding RNA landscape of plasma cell dyscrasias 42
Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma 30
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 30
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 23
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients 21
The non-coding RNA landscape of plasma cell dyscrasias 13
Daratumumab in the treatment of C3 glomerulopathy with monoclonal gammopathy: a case report and literature review 11
Totale 4.653
Categoria #
all - tutte 15.471
article - articoli 15.471
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.942


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.011 0 0 0 0 127 164 167 103 122 165 123 40
2020/2021435 22 37 20 34 52 27 27 40 31 56 51 38
2021/2022566 21 26 37 70 25 47 30 113 28 52 30 87
2022/2023648 72 71 9 76 106 93 6 39 89 12 71 4
2023/2024433 14 58 14 57 43 91 23 45 12 5 29 42
2024/2025274 43 71 31 83 46 0 0 0 0 0 0 0
Totale 4.653